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Yin Yang 1 (YY1) is highly expressed in various types
of cancers and regulates tumorigenesis through mul-
tiple pathways. In the present study, we evaluated
YY1 expression levels in breast cancer cell lines, a
breast cancer TMA, and two gene arrays. We observed
that, compared with normal samples, YY1 is gener-
ally overexpressed in breast cancer cells and tissues.
In functional studies, depletion of YY1 inhibited the
clonogenicity, migration, invasion, and tumor forma-
tion of breast cancer cells, but did not affect the clono-
genicity of nontumorigenic cells. Conversely, ectopi-
cally expressed YY1 enhanced the migration and
invasion of nontumorigenic MCF-10A breast cells. In
both a monolayer culture condition and a three-di-
mensional Matrigel system, silenced YY1 expression
changed the architecture of breast cancer MCF-7 cells
to that resembling MCF-10A cells, whereas ectopically
expressed YY1 in MCF-10A cells had the opposite ef-
fect. Furthermore, we detected an inverse correlation
between YY1 and p27 expression in both breast can-
cer cells and xenograft tumors with manipulated YY1
expression. Counteracting the changes in p27 expres-
sion attenuated the effects of YY1 alterations on these
cells. In addition, YY1 promoted p27 ubiquitination and
physically interacted with p27. In conclusion, our data
2120suggest that YY1 is an oncogene and identify p27 as a
new target of YY1. (Am J Pathol 2012, 180:2120–2133; DOI:
10.1016/j.ajpath.2012.01.037)
Breast cancer development and progression are associ-
ated with both genetic and epigenetic alterations related
to different signaling pathways.1 Genetic mutation of tu-
mor suppressors such as BRCA12 have been correlated
with breast cancer. Epigenetic mechanisms contribute to
the disease phenotypes by both directly altering the ex-
pression of cancer-related genes and affecting the pen-
etrance of variants with genetic vulnerability. Deregulated
expression of proliferative or oncogenic genes due to
aberrant DNA methylation and histone modifications has
a crucial role in breast cell malignancy.3,4
The multifunctional protein Yin Yang 1 (YY1) is an im-
portant regulator of differential epigenetic regulation in
gene expression and protein modifications. As a ubiqui-
tously expressed and highly conserved protein from Xe-
nopus to human, YY1 functions as a transcription factor to
either activate or repress its target genes, depending on
its recruited cofactors.5–8 The domain architecture and
transcriptional activity of YY1 have been extensively stud-
ied.9 Some YY1-recruited proteins such as p300,
HDAC1, Mdm2, Ezh2, and PRMT1 mediate differential
histone modifications. YY1 regulates many genes with
protein products essential to cell proliferation and differ-
entiation (reviewed in references 6 through 10), and YY1
gene expression is regulated by various growth stimuli.7
In addition, YY1 is one of the Polycomb Group proteins
that contribute to the aberrant epigenetics of cancers.11
The functional role of YY1 has been characterized in the
developmental studies of Drosophila melanogaster using
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like.12,13 YY1 is one of the few Polycomb Group proteins
that can directly bind DNA and recruit other Polycomb
Group proteins to establish and maintain gene silencing.
Many lines of evidence suggest a regulatory role of
YY1 in cancer development. YY1 regulates expression of
many cancer-related genes such as MYC (alias c-myc)
and c-Fos.14,15 In addition, YY1 is associated with many
proteins with critical regulatory functions such as p300,
HDAC1, Ezh2, Mdm2, p53, Rb, and mTOR.16–21 In par-
ticular, YY1-Mdm2 interaction has a role in enhancing
Mdm2-mediated p53 ubiquitination and degrada-
tion.19,22 Furthermore, YY1 is highly expressed in breast
cancer, and cooperates with activator protein 2 to stim-
ulate expression of ERBB2 (Her2/neu),23,24 a proto-onco-
gene overexpressed in approximately 30% of breast can-
cers and generally correlated with a poor prognosis.25
Recently, we have demonstrated the regulation of YY1
expression by G-quadruplex, a four-stranded DNA struc-
ture formed by non–Watson-Crick base pairing that is
typically present in the promoters of oncogenes.26 These
data strongly suggest that YY1 is an oncogene in tumor-
igenesis. Consistently, increased YY1 expression has
been reported in multiple human cancers (reviewed in
references 8, 27, and 28).
In the present study, we demonstrated that YY1 is
generally overexpressed in breast cancer and is essen-
tial to the tumorigenicity of breast cancer cells. Further-
more, ectopic YY1 confers many oncogenic properties to
nontumorigenic breast cells. p27 levels inversely corre-
lated with manipulated YY1 expression, and YY1 posi-
tively regulated p27 ubiquitination. These data support
the concept that YY1 has an oncogenic role in breast
cancer development.
Materials and Methods
Antibodies and DNA Vectors for Gene
Expression and Knockdown
The antibodies, their catalog numbers and vendors
include YY1 (H-414, sc-1703; and H-10, sc-7341;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA), Ezh2
(AC22; Cell Signaling Technology, Inc., Beverly, MA),
p27 (610241; BD Biosciences, Franklin Lakes, NJ),
Ki-67 (sp6; NeoMarkers, Inc., Freemont, CA), -actin
(MAB1501; Chemicon International Inc., Temecula, CA),
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(10R-G109A; Fitzgerald Industries International, Inc.,
Acton, MA).
We generated lentiviral vector pSL5 and pSL9 using a
chicken -actin promoter29 to drive inserted cDNA and to
carry anti-puromycin and anti-blasticidin genes, respec-
tively. The short hairpin RNA (shRNA) was designed
based on our previously published methods.30,31 The
target sequences included a scrambled control (5=-
GGGACTACTCTATTACGTCATT-3=), human YY1 (5=-
GGGAGCAGAAGCAGGTGCAGAT-3=), and human p27
(5=-GGCTAACTCTGAGGACACGCATT-3=). The induc-
ible H1 promoter with a tetracycline regulator site presentdownstream of the H1 promoter was used for doxycycline
(Dox)–induced shRNA expression in tetracycline regula-
tor–containing cells. Other lentiviral vectors have been
described previously.19
Cell Culture, Lentiviral Production, and Infection
Human mammary epithelial cells (HMECs), nontumori-
genic breast cell line MCF-10A, and tumorigenic breast
cell lines MCF-7, MDA-MB-231, SK-BR-3, ZR-75-1, BT-
474, and HEK (HMEC immortalized by SV40 large-T an-
tigen, the telomerase catalytic subunit, and H-Ras)32
were cultured according to the protocol of the American
Type Culture Collection or the cited literature. 293FT cells
were cultured in DMEM (Dulbecco’s modified Eagle’s
medium) supplied with 10% fetal bovine serum. MCF-10A
is a spontaneously immortalized and nontransformed hu-
man mammary epithelial cell line and exhibits many fea-
tures of normal breast epithelium.33 Therefore, MCF-10A
has been used as a nontumorigenic control in many
previous breast cancer studies. MCF-7 and MDA-MB-
231 breast cancer cell lines, used in our functional stud-
ies, were derived, respectively, from pleural effusion from
a patient with breast cancer34 and the mammary gland of
another patient with breast cancer.35
Lentivirus was produced as described previously36 by
transfecting 293FT cells with a lentiviral plasmid and
three packaging plasmids (pMDLg/pRRE, pRSV-REV,
and pVSV-G) using the calcium phosphate precipitation
method. To infect cells, concentrated lentivirus was
added to the medium with 8 g/mL polybrene and incu-
bated for 6 hours before reverting to normal medium.
Tissue Microarray
The generation and applications of the breast cancer
TMA process have been described previously.37,38 In
brief, one TMA set consists of eight slides; each slide
(60  10 mm) contains the cores of normal breast, tonsil,
and liver as reference tissues, and at least two cores of
breast cancer samples from each patient (de-identified).
The analysis was based on the intensity of staining and
percentage of stained tumor cells by two observers.
Sample scoring was blinded to patient ethnicity. Intensity
was scored from 0 to 2, where 0 was negative for
staining and 2 indicated intense staining. The range of
criteria was established by first analyzing a series of
randomly selected breast cancer tissues for YY1 expres-
sion using our standardized method. Among these sam-
ples, we selected specific blocks as standards for 0, 1,
and 2 intensity. Intensity in the TMA samples was de-
termined by visual comparison with these reference stan-
dard blocks, and percentages of tumor were defined as
0% to 10%, 11% to 50%, 51% to 75%, and 76% to 100%
breast tumor cell staining. Using a spreadsheet (Excel;
Microsoft Corp., Redmond, WA), the mean score was
obtained by multiplying the intensity score by the per-
centage of stained tumor cells, and the results were
summed. This overall score was averaged with the num-
ber of cores studied for that patient. If there was no tumor,
no score was given.
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Mammary cells were trypsinized and fixed using ethanol.
The cells were then pelleted, resuspended in PBS con-
taining 50 g/mL propidium iodide, 0.1 mg/mL RNase A,
and 0.05% Triton X-100, and filtered using cell strainers
(40 m; BD Biosciences). After at least 20 minutes of
incubation on ice, the cells were analyzed via fluores-
cence-activated cell sorting using a flow cytometer (Ac-
curi C6; BD Biosciences).
Clonogenic Assay and Cell Staining
Clonogenic assays were performed as previously de-
scribed.39 Fluorescent staining of actin in cells was
conducted according to a previously published proce-
dure40 using Alexa Fluor 555 phalloidin (Invitrogen
Corp., Carlsbad, CA).
Three-Dimensional Matrigel Culture of Breast
Cells
These procedures generally were performed using a pre-
viously published method.41,42 Each well of a 24-well
plate was coated with 200 L Matrigel (BD Biosciences),
and the plate was incubated at 37°C to allow the base-
ment membrane to solidify. Meanwhile, cells were
trypsinized and resuspended in 5 mL normal culture me-
dium. The cells were spun at 150  g for 5 minutes, and
gently resuspended in 5 mL assay medium (DMEM/F12
medium containing 2% horse serum, 50 ng/mL epidermal
growth factor, 0.5 g/mL hydrocortisone, 0.1 g/mL chol-
era toxin, antibiotics, and 4% collagen). After dilution to a
final density of 5000 cells/mL in the assay medium, 1 mL
of the suspended cells was added on top of the solidified
collagen in the 24-well plate. The cells were allowed to
grow in a 5% CO2 humidified incubator at 37°C for 10 to
15 days, after which they were stained with propidium
iodide and subjected to microscopic analysis.
Breast Cancer Xenograft Study
This mouse model study was performed according to a
protocol approved by the Institutional Animal Care and
Use Committee of Wake Forest University School of Med-
icine. MDA-MB-231 cells (4  106 in 150 L) stably
integrated with an expression cassette of firefly luciferase
were infected with lentivirus carrying Dox-inducible con-
trol shRNA or inducible-YY1 shRNA. The transduced
cells were injected subcutaneously into the flank regions
of 8- to 12-week-old female nude mice supplied with
normal water (control) or water containing 1.5 mg/mL Dox
(10 mice per group for a total of 40 mice). Tumors were
measured twice a week using a Vernier caliper, and
tumor volumes were calculated using the equation V 
1/2(Length Width2).43 Mice with xenografts and control
mice without grafts were anesthetized using 2% isoflu-
rane and then injected intraperitoneally with 150 mg/kg
luciferin, and tumors were imaged using the IVIS 100
System (Xenogen Corp., Alameda, CA). Up to five mice
were placed in the light-tight imaging chamber of theimaging system, and images of emitted photons were
collected by the cooled charge-coupled device camera
over 1 to 3 minutes. Four weeks after cell implantation, all
mice were sacrificed via CO2 asphyxiation. Tumor xeno-
grafts were collected, photographed, and analyzed using
immunostaining and Western blot analysis.
Real-Time RT-PCR Analysis
Total RNA from cells was extracted using TRIzol reagent
(Invitrogen Corp.). To determine mRNA levels of YY1 and
p27, 2 g RNA was incubated with 0.5 g/L oligo dT
primer (Promega Corp., Madison, WI) at 70°C for 5 min-
utes. The following reverse transcriptase mix was then
added and incubated at 42°C for 1 hour: 5 L 5 MMLV
(Moloney murine leukemia virus) buffer, 5 L 10 mmol/L
deoxyribonucleotide triphosphate, 0.6 L ribonuclease
inhibitor (RNasin; Promega Corp.) 1 L MMLV reverse
transcriptase, and 13.4 L nuclease-free water. Quanti-
tative PCR analysis using Taqman gene expression as-
says was then performed for YY1 and p27 expression,
and data were normalized to GAPDH expression (Ap-
plied Biosystems, Inc., Foster City, CA). All analyses were
performed using a sequence detection system (ABI7000;
Applied Biosystems). The CT method44 was used to
calculate relative expression.
p27 Stability Determination
Experiments were conducted as previously described.45
To test the effect of increased YY1 on p27 stability, we
used MCF-10A cells infected with pSL5 and pSL5/YY1
lentiviruses. To test the effect of endogenous YY1 silenc-
ing on p27 stability, we used MCF-7 cells with inducible-
control shRNA or inducible-YY1 shRNA. The concentra-
tion of cycloheximide for MCF-10A cells was 60 g/mL,
and for MCF-7 cells was 45 g/mL.
Cell-Based p27 Ubiquitination Assay
The experiments were performed according to a previ-
ously published procedure.46 To test the effect of YY1
increase on p27 ubiquitination, expression vectors for
pSL5/p27 and pCMV/His6-ubiquitin (0.4 g each) were
co-transfected with different amounts (0.2 and 0.4 g) of
pcDNA3/YY1, in the absence or presence of pSL5/Skp2
(0.4 g), into 293T cells in 6-cm dishes. To test the effect
of YY1 knockdown on p27 ubiquitination, 293T cells were
infected with lentiviruses expressing control shRNA or
YY1 shRNA. After 24 hours, the cells were transfected
with plasmids expressing pCMV/His6-ubiquitin, pSL5/
p27, and pSL5/Skp2 (0.4 g each). Two days after trans-
fection, the cells were treated using proteasome inhibitor
MG132 (20 mol/L) for 4 hours before harvesting. A por-
tion (10%) of the cell lysates was directly analyzed using
Western blot analysis using p27, YY1, Skp2, and -actin
antibodies. The other portion of cell lysates was treated
using Ni-NTA beads (Qiagen GmbH, Hilden, Germany)
and analyzed via p27 immunoblotting.
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In vitro protein binding studies were performed as previ-
ously described.45
Statistical Analysis
Data in reporter assays andWST-1 assays are given asmean
(SD).Comparisonsbetween twogroups for a singleparameter
were performed using Student’s t-test. Statistical analyses
were performed using commercially available software
(SigmaPlot 11.0; Systat Software Inc., San Jose, CA). The
criterion for statistical significance was set at P  0.05.
Results
YY1 Expression in Breast Cancer Cell Lines,
TMA, and Breast Cancer Gene Arrays
We first determined YY1 expression in a panel of com-
monly used breast cancer cell lines, MCF-7, MDA-MB-
231, SK-BR-3, ZR-75-1, BT-474, and HEK,32 with HMEC
and MCF-10A cells as controls. Cell lysates with an equal
protein amount from these cell lines were analyzed using
Western blot analysis with antibodies for YY1(H-414),
Ezh2, and -actin. As a histone methyltransferase, Ezh2
is a biomarker of aggressive breast cancer and promotes
neoplastic transformation of breast epithelial cells.47 The
levels of -actin or GAPDH did not always show equal
intensity using Western blot analysis; BT-474 cells re-
peatedly exhibited low levels of -actin (Figure 1A) and
GAPDH (not shown), which suggested that they could not
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)be used as normalizing controls. Inasmuch as an equal
amount of total protein was loaded in each line, we directly
quantified the relative YY1 and Ezh2 expression based on
the signal of their blots (Figure 1A). In all six cancer cell
lines, YY1 expression was increased by 5.7-fold or greater
versus HMECs, and by 1.8-fold or greater versus MCF-10A
cells (Figure 1A). Similarly, Ezh2 was also elevated by 2.2-
fold or greater compared with MCF-10A cells, and its ex-
pression in HMECs was not detected (Figure 1A).
To study YY1 expression in breast cancer tissues, we
first validated the specificity of YY1 antibody H-10 (Santa
Cruz Biotechnology) in MCF-7 cells by co-transfecting
either the control or YY1 shRNA with a vector expressing
enhanced version of green fluorescent protein (EGFP) at
a molar ratio of 5:1 (shRNA/EGFP). Thus, EGFP-positive
cells should also contain co-transfected shRNA. Cells
transfected with EGFP and control shRNA exhibited YY1
levels similar to those of EGFP-negative (nontransfected)
cells (see Supplemental Figure S1A at http://ajp.
amjpathol.org). However, cells containing both EGFP and
YY1 shRNA exhibited markedly decreased YY1 expres-
sion. Similar results were also obtained with YY1 (H-414)
antibody (data not shown). Therefore, YY1 (H-10) and
YY1 (H-414) antibodies did not recognize any other pro-
tein with a comparable affinity to YY1 protein in MCF-7
cells, which suggests their high specificity. Consistent
with results of Western blot analysis, the immunohisto-
chemical studies indicated a marked increase in YY1 in
MCF-7 cells compared with MCF-10A cells, with YY1
predominantly localized in nuclei (see Supplemental Fig-
ure S1B at http://ajp.amjpathol.org). The YY1 (H-10) anti-
body was used to determine YY1 protein expression in a
l Cancer
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Figure 1. YY1 expression in breast cancer cell
lines and patient samples. A: YY1 and Ezh2 ex-
pression in nontumorigenic and tumorigenic
breast cell lines. Total cell lysates of different cell
lines (labeled on the top) were analyzed using
Western blot analysis (antibodies labeled on the
left). HMEC and MCF-10A cells were used as non-
tumorigenic controls. The increases in YY1 and
Ezh2 protein levels in these six tumorigenic cell
lines as compared with HMEC and/or MCF-10A
cells are indicated under each blot. B: YY1 expres-
sion in a TMA study. The TMA derived from 120
patients37,38 was blotted using a YY1 antibody (H-
10; Santa Cruz Biotechnology). The difference was
determined using the Kruskal-Wallis test. *P 
0.046. C: Relative YY1 expression in different
breast cancer subtypes of the Uppsala cohort (258
patient samples). The nomenclature (base-like,
HER2 positive, luminal A, luminal B, and normal-
like) refer to intrinsic breast cancer subtypes ac-
cording to a previously reported method.48 *P 
0.051, **P  0.0011, ***P  8.4  107, ****P 
5.9  105, and *****P  0.043. D: Gene array
analysis of YY1 expression. In a publicly available
data set of a gene microarray,49 YY1 expression in
samples of invasive ductal carcinoma (IDC, 23) is
significantly higher than normal breast samples from
tissues adjacent to tumors (ATT, 10) and from reduc-
tion mammoplasties (RM, 10). Data are the average
values generated by three YY1 probes (200047_s_at,
201901_s_at, and 213494_s_at). Their sequences are
available from Affymetrix, Inc. *P  6.9  105,
**P  0.0028, and ***P  0.026.Norma
RM
(n=10)
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breast tissues as controls. We observed that YY1 was
significantly overexpressed in breast cancer samples
compared with normal breast samples (Figure 1B; P 
0.046), and YY1 signal was detected primarily in nuclei,
with some samples showing cytoplasmic staining (see
Supplemental Figure S1C at http://ajp.amjpathol.org).
To determine whether YY1 is generally overexpressed
at the transcription level in breast cancer, we analyzed a
set of Affymetrix gene microarray data derived from the
Uppsala breast cancer cohort consisting of 258 patient
samples.50 To estimate where YY1 expression levels can
be located among all other genes in this array, we used
the negative control (Bacillus subtilis) and the average of
the genes with the 10% lowest expression (from 2230
probes) to represent the base or low signal intensity of
this array. In addition, we analyzed -actin, GAPDH, and
the average of the 10% highest expressed genes (also
from 2230 probes) to represent the high signal intensity of
this array. We then compared YY1 expression with sev-
eral known breast cancer-related genes including Ezh2,
HER2, ER-, BRCA1, and Ki-67. The YY1 signal was
determined on the basis of three different YY1 probes
(213494_s_at, 201901_s_at, and 200047_s_at) that
match three regions of the YY1 transcript (see Supple-
mental Figure S1D at http://ajp.amjpathol.org). Overall
YY1 signal intensity was generally higher than that of
Ezh2, HER2, ER-, and Ki-67 (see Supplemental Figure
S1E at http://ajp.amjpathol.org), which are well character-
ized for their overexpression in breast cancer.
We also analyzed YY1 expression of the breast cancer
samples in this cohort on the basis of their subtypes,
which were grouped using a previously reported
method.48 Compared with normal-like samples, YY1 ex-
pression is significantly increased in groups of basal-like,
HER2-positive, and luminal A and luminal B tumor tissues
(P  0.0051) (Figure 1C). Among these four groups, we
observed only a significantly higher YY1 expression in the
samples of luminal B subtype compared with the basal-
like samples (P  0.043). However, we did not detect a
significant change in YY1 gene expression between es-
trogen receptor (ER)–positive and ER-negative samples
(P  0.583). To compare YY1 gene expression in breast
cancer versus normal tissues, we studied another Af-
fymetrix gene array data set containing 10 normal breast
samples from reduction mammoplasty procedures, 10
samples collected from normal tissues adjacent to breast
tumors, and 23 invasive ductal carcinomas.49 YY1 expres-
sion was significantly increased in invasive ductal carcino-
mas compared with normal breast samples (P  6.9 
105) and normal samples adjacent to tumors (P 0.0028)
(Figure 1D). In summary, results of our studies strongly
indicated that YY1 is overexpressed in breast cancer.
Manipulated YY1 Expression Affects the
Migration, Invasiveness, Clonogenicity, and
Cell Cycle Profiles of Mammary Cells
As we observed the significant up-regulation of YY1 in
breast cancer tissues and cell lines, we wonderedwhether the aberrantly expressed YY1 has any biological
effect in mammary cells. We studied the effects of ecto-
pic YY1 expression in MCF-10A cells, which have rela-
tively low YY1 levels, and YY1 silencing in MCF-7 and
MDA-MB-231 cells, which have high YY1 levels.
We first infected MCF-10A cells with pSL5 vector or
pSL5/YY1 lentivirus. In the wound-healing assay, ectopic
YY1 markedly enhanced MCF-10A cell migration when
compared with the control (Figure 2A). In the Boyden
chamber assay, MCF-10A cells transduced by pSL5/YY1
exhibited significantly increased invasiveness when com-
pared with pSL5 vector (Figure 2B). We also performed
clonogenic assays using these MCF-10A cells. Because
MCF-10A cells did not form well-isolated colonies, their col-
onies could not be counted. We used Adobe Photoshop
11.0.2 (Adobe Systems Inc., McLean, VA) to quantify the
pixels of MCF-10A cell colonies stained with crystal violet.
YY1 overexpression significantly increased the area cov-
ered by the colonies when compared with the vector control
(P  0.05) (Figure 2C), which suggests that ectopic YY1
expression increased survivability of MCF-10A cells. In
these studies, YY1 expression was always monitored using
Figure 2. Effects of manipulated YY1 expression on the migration, invasion, and
clonogenicity of breast cells. MCF-10A (A–C) andMCF-7 (D–F) cells with ectopically
expressed YY1 and Dox-induced YY1 shRNA, respectively. In the scratch assays to
test cell migration (A andD), dashed lines indicate edges of themonolayer cell gaps
on the dishes. In the Boyden chamber assays to test cell invasiveness (B and E), the
results were quantified. *P 0.05. In the clonogenic assay to test cell clonogenicity
(C and F), areas of MCF-10A cells were quantified in pixels, and MCF-7 cells by
number of colonies. Insets in C and F represent Western blots of YY1 ectopic
expression and Dox-induced knockdown, respectively.Western blot analysis (Figure 2C).
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cells, we used Dox-inducible shRNA vectors. Silencing
endogenous YY1 decreased migration of MCF-7 and
MDA-MB-231 cells (Figure 2D; see also Supplemental
Figure S2A at http://ajp.amjpathol.org). In addition, Boy-
den chamber assays also indicated reduced invasive-
ness of these two cell lines when YY1 was knocked down
(Figure 2E; see also Supplemental Figure S2, B and C, at
http://ajp.amjpathol.org). In the clonogenic studies, YY1
silencing significantly decreased the colony formation of
MCF-7 cells (Figure 2F). In these studies, Dox-induced
control shRNA did not produce these phenotypic
changes (data not shown). These data suggest that ele-
vated YY1 expression has a critical role in promoting or
sustaining breast cancer cell migration, invasion, and
clonogenicity. In these studies, YY1 expression was rou-
tinely monitored using Western blot analysis (Figure 2F; see
also Supplemental Figure S2D at http://ajp.amjpathol.org).
To examine whether YY1 depletion exerts the same
effects on both nontumorigenic and tumorigenic cells, we
infected MCF-7 and MCF-10A cells with lentiviruses car-
rying constitutive expression cassettes of either YY1
shRNA or control shRNA and a puromycin selection
marker. The infected cells were cultured in puromycin-
containing medium and studied using clonogenic as-
says. Again, because of the diffuse nature of MCF-10A
cells, we used photoshop software to quantify the pixels
of stained cells in each dish. In contrast, MCF-7 cells
formed well-isolated colonies that could be counted using
Quantity One 4.2.2 software (BioRad Laboratories, Inc.,
Hercules, CA). We observed that YY1 depletion did not
significantly change the clonogenicity of MCF-10A cells but
markedly decreased that of MCF-7 cells (see Supplemental
Figure S3, A and B, at http://ajp.amjpathol.org). We also
tested ZR-75-1 and MDA-MB-231 cells, and obtained re-
sults similar to those for MCF-7 cells (data not shown).
These results indicate that YY1 is essential to independent
proliferation and colony formation of breast cancer cells but
not to that of nontumorigenic MCF-10A cells, implicating the
potential of YY1 as a therapeutic target of breast cancer.
We further tested the effects of YY1 changes on cell
cycle profiles of mammary cells. Ectopic YY1 increased
the G1 phase and decreased the G2/M phase of MCF-
10A cells (see Supplemental Figure S4A at http://ajp.
amjpathol.org). MCF-7 and MDA-MB-231 cells showed a
differential response to YY1 silencing in their cell cycle
profiles. Although both cells showed a slightly increased
G2/M phase, the changes in the G1 and S phases were
different (see Supplemental Figure S4, B and C, at http://
ajp.amjpathol.org). Overall, we did not observe large al-
terations in cell cycle profiles of these mammary cells in
response to changes in YY1 levels.
Manipulated YY1 Expression Changes
Mammary Cell Architecture
MCF-10A cells exhibit a spindle shape, whereas MCF-7
cells form irregular clusters. We tested the effects of manip-
ulated YY1 expression on the architecture of these two cell
lines in monolayer culture conditions.We observed that pSL5/YY1 lentivirus infection could
induce more MCF-10A cells to undergo mitosis and grow
in a highly aggregative architecture when compared with
pSL5 vector-infected cells (Figure 3A). In contrast,
MCF-7 cells with silenced YY1 markedly lost the cell-cell
contact observed in the control shRNA–treated cells (Fig-
ure 3B). The effects of YY1 increase on MCF-10A cell
architecture could also be observed in a clonogenic
study. pSL5 vector–infected MCF-10A cells formed
spread-out spindle-shaped colonies; however, the cells
with ectopic YY1 generated colonies with more compact
and rugged shapes (Figure 3C). These data suggested
that YY1 has a role in regulating the morphologic
changes in mammary cells.
YY1 Knockdown Reduces Tumor Formation by
MDA-MB-231 Cells in a Xenograft Mouse
Model
To determine whether YY1 overexpression in breast can-
cer cells is essential to tumor formation, we performed
xenograft studies in athymic nude mice using MDA-MB-
231 cells with stably integrated expression cassettes for
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in Figure 4A (10 mice per group). Tumors in group 1
(inducible-YY1 shRNA, Dox) were smaller than those in
the other three groups (see Supplemental Figure S5A at
http://ajp.amjpathol.org). When imaged using the IVIS
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AJP May 2012, Vol. 180, No. 5control shRNA, Dox), and final tumor weights between
groups showed statistically significant differences (P 
0.017 for group 1 versus group 2; P  0.0001 for group
1 versus group 3) (Figure 4C). Groups 3 and 4 demon-
strated similar growth rates and final tumor weights (P 
0.47) (Figure 4C).
Dox-induced YY1 silencing was confirmed using West-
ern blot analysis (Figure 4D), supporting the notion that
YY1 is essential for tumor formation in this mouse model.
When YY1 was knocked down in the tumors with induc-
ible-YY1 shRNA Dox, Ki-67 staining was reduced when
compared with the tumors with inducible-YY1 shRNA
Dox (Figure 4E), which suggested that silenced YY1 led
to decreased cell proliferation in these tumor xenografts.
p27 Is a Potential Downstream Target of YY1 in
Mediating Mammary Cell Tumorigenesis
We and others have reported the negative regulation of
p53 by YY1.19,22,51–53 However, p53 is deficient in 50%
of cancers and approximately 26% of breast cancers.54
To determine whether YY1 has a role in mammary cell
tumorigenesis, we explored other potential YY1-regu-
lated mechanisms that may contribute to these pheno-
typic changes described. Multiple studies demonstrated
the functions of p27 in regulating breast cancer develop-
ment (reviewed in references 55 and 56) and controlling
cell architecture and motility.57 p27 is inactivated primar-
ily through posttranslational modifications in cancers (re-
viewed in reference 58); YY1 has been implicated in mod-
ulating various protein modifications of histone and
nonhistone proteins (reviewed in reference 7). Therefore,
we wanted to determine whether YY1 regulates the func-
tion or expression of p27 in breast epithelial cells. We first
tested p27 expression in the cell lines with manipulated
YY1 expression. In MCF-10A and MCF-7 cells with no or
low malignancy, ectopically expressed YY1 led to re-
duced expression of endogenous p27 (Figure 5A). In
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Figure 5. Effects of manipulated YY1 expression on endogenous p27 levels
in MCF-7 and MCF-10A cells. B: Effects of silenced YY1 expression on endogtumorigenic MCF-7 cells, MDA-MB-231 cells, and 7 of the10 MDA-MB-231 xenografts (Figure 5B), YY1 knockdown
resulted in increased p27 expression when compared
with their corresponding controls. Consistently, in several
other breast cell lines expressing high levels of YY1, we
also observed reduced p27 expression compared with
that in MCF-10A cells (see Supplemental Figure S6 at
http://ajp.amjpathol.org). These data suggest that YY1
may act as a negative regulator of tumor suppressor p27.
Effects of YY1 on Architecture and Proliferation
of MCF-10A and MCF-7 Cells in Three-
Dimensional Matrigel Culture Are Reversed by
Adjusting p27 Expression
Inasmuch as altered YY1 expression changed the archi-
tecture of mammary cells in a monolayer culture condi-
tion, we also studied how YY1 expression affects mam-
mary cell architecture in a 3-D Matrigel culture system.
When we inoculated the same number of cells in the 3-D
Matrigel, we observed that MCF-10A cells generated
many spheroids but that MCF-7 cells formed irregular cell
clusters (see Supplemental Figure S7A at http://ajp.
amjpathol.org). To test the effect of ectopically expressed
YY1 on cell architecture, we seeded MCF-10A cells in-
fected with either pSL5 or pSL5/YY1 lentivirus in the 3-D
Matrigel culture. Whereas pSL5-transduced MCF-10A
cells retained a regular spheroid shape, the transduction
of pSL5/YY1 disrupted this ability (Figure 6A; see also
Supplemental Figure S7B at http://ajp.amjpathol.org),
reminiscent of the effect of ectopic ERBB2 on MCF-10A
cells.42 Inasmuch as we observed negative regulation of
p27 by YY1, we wondered whether this regulation had a
role in this phenotypic change. Therefore, we introduced
exogenous p27 into pSL5/YY1-transduced MCF-10A
cells with pSL9/p27 lentivirus infection carrying a blasti-
cidin selection marker. Ectopic p27 restored the ability of
the YY1-overexpressing MCF-10A cells to form spher-
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Supplemental Figure S7B at http://ajp.amjpathol.org).
Cells infected with pSL9 vector lentivirus did not show this
effect (data not shown). Expression of YY1 and p27 proteins
in these conditions was confirmed using Western blot anal-
ysis (Figure 6B). These data suggest that p27 is an essential
downstream target of YY1 in mediating its morphologic
changes caused by YY1 elevation in MCF-10A cells.
We next studied the effects of YY1 silencing on the
architecture of MCF-7 and MDA-MB-231 cells in 3-D
Matrigel culture. We first tested MCF-7 cells with induc-
ible-YY1 shRNA. When cultured in Dox-negative medium,
these MCF-7 cells still exhibited an irregular clustered
architecture (Figure 6C), like the parental MCF-7 cells.
However, in the presence of Dox that induced YY1 knock-
down, cell clusters became smaller and some spheroid-
like structures were formed, which suggested that YY1
silencing could at least partially restore the differentiating
capability of MCF-7 cells (Figure 6C; see also Supple-
mental Figure S7C at http://ajp.amjpathol.org). Because
YY1 knockdown led to p27 increase, we wondered
whether up-regulated p27 expression had a role in this
phenotypic change. We used pLu-Neo-U6/p27 shRNA to
silence p27 expression in YY1-depleted MCF-7 cells, and
observed that these cells more frequently formed bigger
and irregular clusters (Figure 6C; see also Supplemental
Figure S7C at http://ajp.amjpathol.org), similar to the ar-
chitecture of the control (Dox) or parental MCF-7 cells.
Cells infected with pLu-Neo-U6/control shRNA lentivirus
A    MCF-10A cells
pSL5 vector pSL5/YY1
- Dox
indu-YY1 shRNA
+ Dox
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Figure 6. Effects of YY1 and p27 expression on the morphology of breast cel
on morphology of MCF-10A cells. The cells underwent individual infection w
pSL5/YY1 and pSL9/p27 lentiviruses. B:Western blots of YY1 and p27 expre
were infected by Dox-inducible YY1 shRNA-containing lentivirus and culture
in the presence of Dox. D: Western blots of YY1 and p27 expression of cedid not demonstrate this effect (data not shown). Theseresults suggested that p27 is an essential downstream
target of YY1 in mediating the morphologic changes in
MCF-7 cells in Matrigel. Expression of YY1 and p27 pro-
teins was confirmed using Western blot analysis (Figure
6D). We also tested the effects of YY1 knockdown on the
architecture of MDA-MB-231 cells in Matrigel. Cells with
decreased YY1 formed smaller clusters than did control
shRNA–infected cells; however, YY1 knockdown cells did
not generate polarized structures (see Supplemental Figure
S7D at http://ajp.amjpathol.org). This phenomenon sug-
gested that, unlike MCF-7, MDA-MB-231 cells are more
de-differentiated and YY1 down-regulation is insufficient to
restore normal mammary gland architecture in these cells.
To test the effects of YY1 on cell proliferation, we per-
formed WST-1 assays. Ectopic YY1 expression in MCF-
10A cells infected with pSL5/YY1 significantly increased
cell numbers after 6 days of culture, compared with the
pSL5 vector group (P  0.03) (see Supplemental Figure
S8A at http://ajp.amjpathol.org). This effect was dimin-
ished by restoring p27 expression using pSL9/p27, com-
pared with the same control. In MCF-7 cells carrying
inducible-YY1 shRNA, YY1 silencing induced by Dox
significantly reduced cell numbers when compared with
the Dox condition (P  0.03) (see Supplemental Figure
S8B at http://ajp.amjpathol.org). However, p27 knock-
down did not reinstate cell numbers, which suggests that
p27 reduction was unable to rescue the growth defect
caused by YY1. To determine the exponential prolifera-
tion rates of these cell groups, we plotted the data in
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These lines showed comparable slopes, suggesting that
the observed cell growth difference was not due to the
altered proliferation rates. In these studies, expression of
YY1 and p27 was routinely monitored using Western blot
analysis (data not shown).
YY1 Negatively Regulates p27 Expression at the
Posttranslational Level
We further explored the mechanisms whereby YY1 neg-
atively regulates p27. Inasmuch as YY1 is well known for
its transcriptional activity, we first determined whether
YY1 regulates p27 gene transcription. We performed
real-time PCR assays to assess steady-state p27 mRNA
levels of MCF-10A and MCF-7 cells expressing ectopic
YY1 or silenced endogenous YY1, respectively. Ectopic
YY1 expression in MCF-10A cells did not significantly
change p27 mRNA levels (Figure 7A), although YY1
knockdown increased p27 gene expression in breast
cancer cells, in particular in MDA-MB-231 cells (Figure
7A). We also studied the potential regulation of p27 tran-
scription by YY1 using p27 promoter (prmt) reporter as-
says. We first generated a reporter construct, p27-prmt-
Gluc, which uses the p27 promoter to drive Gaussia
luciferase expression (see Supplemental Figure S9A at
http://ajp.amjpathol.org) and co-transfectedMCF-7 cells by
p27-prmt-Gluc with pcDNA3 vector or pcDNA3/YY1, as well
as a plasmid expressing secreted alkaline phosphatase as
a transfection control. Ectopically expressed YY1 doubled
the relative Gluc activity mediated by the p27 promoter
compared with the vector control (P  0.02) (see Supple-
mental Figure S9B at http://ajp.amjpathol.org), which sug-
gests that increased YY1 does not reduce p27 transcrip-
tion. We then analyzed the correlation between the
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The p27 gene exhibited a slightly positive correlation with
the gene expression of YY1 (r  0.12; P  0.05) (Figure
7B). Overall, these data suggest that the negative regu-
lation of p27 protein levels by YY1 likely does not result
from YY1-mediated transcriptional regulation.
We wondered whether YY1 regulates p27 at the post-
translational level. We first determined p27 stability with
either ectopically expressed YY1 or silenced endoge-
nous YY1. MCF-10A cells infected with pSL5/YY1 or pSL5
vector were treated using 60 g/mL cycloheximide, and
the cells were collected at different times for Western blot
analysis. Ectopic YY1 reduced stability of p27 when com-
pared with the cells infected with the control vector (P 
0.0066) (Figure 8A; see also Supplemental Figure S10A
at http://ajp.amjpathol.org). We also tested YY1 stability in
MCF-7 cells with silenced endogenous YY1 and treated
with 45 g/mL cycloheximide. YY1 depletion increased
the stability of p27 (P  0.0052) (Figure 8B; see also
Supplemental Figure S10B at http://ajp.amjpathol.org).
Previous studies have indicated that p27 turnover is regu-
lated by ubiquitination promoted by its E3 ligase, Skp2.60,61
Therefore, we tested whether YY1 affected Skp2-mediated
p27 ubiquitination by co-transfecting 293T cells with p27,
Skp2, His6-ubiquitin, and two different amounts of YY1.
Ubiquitinated p27 was brought down by Ni-NTA beads
(Qiagen GmbH) and blotted using a p27 antibody. Ectopic
YY1 increased the signal of both monoubiquitinated and
polyubiquitinated p27 (Figure 8C). In the presence of Skp2,
YY1-promoted p27 ubiquitination was slightly enhanced
(Figure 8C). We further studied the effect of YY1 knockdown
on p27 ubiquitination. Because the ubiquitination of endog-
enous p27 was weak and difficult to detect (data not
shown), we transfected plasmids expressing p27, Skp2,
and His6-Ub into 293T cells infected with lentiviruses ex-
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AJP May 2012, Vol. 180, No. 5tion markedly reduced the polyubiquitinated p27, whereas
the monoubiquitinated p27 was likely not affected (Figure
8D). We also performed an in vitro protein binding experi-
ment using His6- and GST-tagged proteins that were ex-
pressed and purified from bacteria. GST-p27, but not GST-
Skp2, could pull down His6-YY1, which suggests direct
interaction of YY1 with p27 but not Skp2 (Figure 8E). In this
experiment, GST served as a negative control, and GST-
p53 served as a positive control, based on our previous
report.19
Discussion
Previous studies have demonstrated the regulatory
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using Western blot analysis using YY1 H-10 antibody.mechanisms of YY1 in various cancer-related signalingpathways such as Mdm2-mediated p53 degradation,
Ezh2- and PRMT1-mediated histone methylation, and
p300/HDAC-mediated histone acetylation/deacetyla-
tion.7,8 Therefore, YY1 likely regulates cancer develop-
ment through multiple signaling pathways. In the present
study, we observed YY1 overexpression in various breast
cancer cell lines, a TMA, and two gene arrays. We dem-
onstrated the effects of manipulated YY1 expression on
mammary cell proliferation, clonogenicity, migration, in-
vasion, and tumor formation. In addition, we revealed that
YY1 negatively regulated tumor suppressor p27. Overall,
our data unequivocally indicate that YY1 has a prolifera-
tive or oncogenic role in breast tumorigenesis.
Our analyses of the Uppsala cohort indicated that YY1
was increased in four subtypes of breast cancer samples
when compared with normal-like tissues. However, we
did not observe a significant change of YY1 expression
between ER-positive and ER-negative samples. It is note-
worthy that a recent study using breast cancer TMA dem-
onstrated a positive correlation between YY1 and ER
expression.62 The apparent inconsistency between that
report and the present study suggests that YY1 positively
regulates ER levels at the posttranslational level.
It is likely that YY1-mediated p27 down-regulation is
independent of YY1-mediated p53 degradation because
the negative regulation of p27 by YY1 could be detected
in both MCF-7 and MDA-MB-231 cells, which contain
wild-type and mutated p53, respectively. Whether there
is any cross-talk between these two signaling pathways
in regulating breast cancer tumorigenesis requires fur-
ther investigation.
In our gene array studies (Figure 1D), YY1 levels were
significantly increased in invasive breast ductal carci-
noma samples when compared with normal tumor-adja-
cent tissue and reduction mammoplasty samples. How-
ever, there was also a significant difference between the
latter two groups (P 0.026). Therefore, it is possible that
these tumor-adjacent tissues exhibited elevated YY1 as
part of a premalignant “field effect” in the tumor-contain-
ing breast. Correspondingly, in a study of YY1 expression
in prostate cancer, prostatic intraepithelial neoplasia
samples also showed increased YY1 levels.63
We detected morphologic changes in MCF-10A and
MCF-7 cells caused by manipulated YY1 expression in a
monolayer culture condition (Figure 3). Ectopic YY1 in-
creased the growth contact of MCF-10A cells, whereas
YY1 silencing in MCF-7 cells produced an opposite ef-
fect. These data indicated that YY1 expression positively
correlated with the nuclear/cytoplasmic ratio, which can
be clearly observed in Figure 3, A and B. Because this
ratio usually increases during cell malignant transforma-
tion, these results suggested an oncogenic role of YY1.
Three-dimensional Matrigel culture systems faithfully
recapitulate the in vivo conditions of mammary
glands.64,65 Previous studies have reported that nontu-
morigenic cells, such as MCF-10A, form spheroid or ac-
inus structures in the 3-D Matrigel culture; however, on-
cogene (such as ERBB2)–transformed or tumorigenic
breast cells do not show this type of orientated or polar-
ized architecture under the same growth conditions.42We have observed that shRNA-mediated YY1 silencing
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ture to that resembling MCF-10A cells. However, YY1
knockdown in MDA-MB-231 cells did not cause this type
of morphologic change. We attribute these results to the
different degrees of malignancy between these two cell
lines. MCF-7 cells do not exhibit the aggressive behavior
of MDA-MB-231 cells in vivo, which could make MCF-7
cells more amenable to reversion to normal mammary
gland architecture on adjustment of epigenetic regulation
such as reducing YY1 expression. However, MDA-MB-
231 cells are highly malignant and de-differentiated, and
exhibit much lower p27 expression than do MCF-7 cells
(see Supplemental Figure S6 at http://ajp.amjpathol.org),
which renders them resistant to morphologic reversion to
normality with the same treatment.
It is noteworthy that manipulated YY1 expression did
not markedly alter cell proliferation rates, although
changes in total cell numbers were detected (see Sup-
plemental Figure S8 at http://ajp.amjpathol.org). This phe-
nomenon could be contributed by other factors that in-
fluence cell growth such as the duration of the lag phase
and confluent density. Lack of alteration of the prolifera-
tion rate may also explain the minor changes observed in
cell cycle profiles of these cells. In our cell growth stud-
ies, restored p27 expression in MCF-10A cells dimin-
ished the increased cell numbers caused by ectopic YY1
expression; however, in MCF-7 cells, p27 knockdown did
not rescue the reduced cell numbers caused by YY1
silencing (see Supplemental Figure S8, A and B, at http://
ajp.amjpathol.org). The essential role of YY1 in other pro-
cesses of breast cancer cells may explain this finding.
The absence of YY1 protein could have seriously per-
turbed these pathways beyond the rescue ability of p27
knockdown. Consistently, in our 3-D Matrigel culture
studies, simultaneous silencing of YY1 and p27 did not
fully restore the architecture of MCF-7 cells to that formed
by the cells without YY1 depletion (see Supplemental
Figure S7C at http://ajp.amjpathol.org).
Although ectopic YY1 could cause multiple transfor-
mation-associated changes in vitro, our in vivo experi-
ments indicated that YY1 overexpression did not lead to
tumor formation of xenografted MCF-10A cells (data not
shown). This result suggests either that ectopic YY1
alone is insufficient to initiate breast tumors or that the
mouse xenograft system does not accurately mirror nat-
urally occurring tumor formation. Multiple oncogenes in-
cluding ERBB2, Ha-ras, EGFR, and Src did not show
tumor formation capability in this system,66,67 although
their oncogenic roles are well recognized. We are cur-
rently generating transgenic mice with mammary gland–
specific YY1 overexpression to determine whether genet-
ically elevated YY1 expression can promote breast
tumorigenesis.
Although most previous reports have focused on YY1
as a transcription factor, several recent studies, including
ours,19,68,69 have demonstrated YY1 regulatory functions
independent of its transcriptional activity (reviewed in
reference 8). In the present study, we observed reduced
p27 protein levels, but not mRNA, when YY1 was ectop-
ically expressed in mammary cells (Figures 5A and 7A).
In the breast cancer samples from the Uppsala cohort,p27 and YY1 gene expression did not show a negative
correlation; rather, they exhibited a weak positive corre-
lation (Figure 7B). These data suggest that overex-
pressed YY1 in breast cancer most likely regulates p27 at
the posttranslational level. In contrast, with silenced en-
dogenous YY1, we observed markedly elevated p27
mRNA levels in both MCF-7 and MDA-MB-231 cells (Fig-
ure 7A) and a significant increase in its protein stability59
(Figure 8B; see also Supplemental Figure S10B at http://
ajp.amjpathol.org). This suggests that both enhanced p27
transcription and protein stabilization contribute to ele-
vated p27 expression under YY1-depleted conditions.
YY1 overexpression, but not its depletion, commonly oc-
curs in most human cancers.7 Therefore, the stimulatory
effect of YY1 on p27 ubiquitination likely contributes to its
negative regulation of p27 stability in breast cell tumori-
genesis. The half-life of p27 in MCF-10A cells was much
longer than that of MCF-7 cells (see Supplemental Figure
S10 at http://ajp.amjpathol.org). This is not surprising be-
cause p27 is primarily regulated by its stability through
protein modifications.70 Unlike the regulation of Mdm2-
mediated p53 ubiquitination by YY1, we did not observe
a direct interaction between YY1 and Skp2, the E3 ligase
of p27 (Figure 8E). In addition, the presence of Skp2 just
modestly enhanced YY1-promoted p27 ubiquitination
(Figure 8C). The mechanism underlying YY1-mediated
p27 ubiquitination is unclear and deserves further inves-
tigation. Of note, we could successfully restore p27 levels
in MCF-10A cells expressing ectopic YY1, even though
YY1 antagonized p27 expression. A possible explanation
for this result is that ectopically introduced p27 over-
whelmed or saturated the antagonism caused by YY1
increase in these cells.
Although most of the literature indicated an oncogenic
role of YY1 in tumorigenesis, several reports also sug-
gested some likely anticancer activities of YY1. YY1 ac-
tivated the transcription of HLJ1, a suppressor of tumor
invasion,71 and positively regulated BRCA1.72 However,
the reported cancer-promoting activities of YY1 clearly
override its anticancer potential.8 We predict that the
overall outcome of YY1-regulated processes relies on the
oncogenic stimuli, cell types, and interplay with its re-
cruited cofactors, the availability of which may be altered
under different physiologic conditions.7
YY1 regulates multiple epigenetic processes that are
involved in cancer development. Therefore, overex-
pressed YY1 in breast cancer likely contributes to its
characteristic aberrant epigenetic changes. Unlike ge-
netic alterations, epigenetic changes are mostly revers-
ible. Therefore, it is possible to reverse epigenetic abnor-
mality and reduce tumorigenicity of breast cancer by
targeting YY1 or its regulated signaling pathways. This
may help to achieve the ultimate goal of adjusting epige-
netic regulation and reverting breast cancer cells to nor-
mal cells. Multiple recent studies have suggested the
potential of YY1 as a therapeutic target in cancer. Our
data show that YY1 depletion markedly reduced the
clonogenicity of MCF-7 and MDA-MB-231 cells but did
not substantially affect nontumorigenic MCF-10A cells.
These observations suggest that targeting YY1 poses a
minimal risk of damage to normal breast tissues.
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